Disney, ARRIS International, Opko Health Upgraded

Disney, ARRIS International, and Opko Health shares are on analysts' bullish radar today

Mar 14, 2017 at 9:43 AM
facebook twitter linkedin

Analysts are weighing in on ESPN parent Walt Disney Co (NYSE:DIS), communications stock ARRIS International plc (NASDAQ:ARRS), and diagnostics firm Opko Health Inc. (NASDAQ:OPK). Here's a roundup of today's bullish brokerage notes on DIS, ARRS, and OPK shares.

Disney Stock Taps New High After Upgrade

DIS stock is trading at fresh annual highs today, up 0.8% at $112.46, after Guggenheim upgraded the shares to "buy" from "neutral." This is just be more of the same for Walt Disney Co, which certainly hasn't missed the "Trump rally," gaining nearly 23% since its November low. Options traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have been betting on more upside, too. DIS stock has a 10-day call/put volume ratio of 3.36 across these exchanges, which rests just 6 percentage points from a 52-week high. 

Goldman Sachs Says Buy ARRIS International Shares

Goldman Sachs this morning raised its opinion on ARRS to "buy" from "neutral," while increasing its price target to $32 from $29, expecting increased growth early this year, and saying "current valuation is attractive." Most brokerage firms share this upbeat opinion of ARRIS International stock, with six of seven analysts deeming it a "buy" or "strong buy," and not one "sell" rating on the books. Up 4.4% at $26.08 this morning, ARRS stock has lost ground since notching a 52-week high of $31.52 in early January, but still sports a 20.6% year-over-year lead. 

Guggenheim Expects Opko Stock to Triple

Guggenheim slapped a fresh "buy" rating on OPK this morning, setting an ambitious price target of $25 -- territory never before explored -- saying the company's transition to new therapeutic areas is "underappreciated." The stock needed a boost, with the shares dropping from their December peak above $12 to trade at $8.09. If Opko Health can make a comeback on the charts, it could benefit from a short-squeeze situation. At the moment, a staggering 23 days' worth of buying power is controlled by short sellers, based on average daily trading volumes. 

Get a jump-start on the day's stock market news with Schaeffer's free Opening View newsletter.

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!